Claims for Patent: 8,431,532

Summary for Patent: 8,431,532

Title:	FZD8 extracellular domains and FZD8 extracellular domain fusion molecules and treatments using same
Abstract:	Methods of treatment using Fzd8 extracellular domains (ECDs), Fzd8 ECD fusion molecules, and/or antibodies that bind Fzd8 are provided. Such methods include, but are not limited to, methods of treating obesity and obesity-related conditions. Fzd8 ECDs and Fzd8 ECD fusion molecules are also provided. Polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules are provided. Methods of making and using Fzd8 ECDs, Fzd8 ECD fusion molecules, and antibodies that bind Fzd8 are also provided.
Inventor(s):	Brennan; Thomas (San Jose, CA), Lee; Ernestine (Kensington, CA), Smith; Steven (San Francisco, CA)
Assignee:	Five Prime Therepeutics, Inc. (South San Francisco, CA)
Application Number:	13/169,900
Patent Claims:	1. A method of lowering free fatty acid levels in a subject with high free fatty acid levels comprising administering to the subject an effective amount of a frizzled-8 (Fzd8) extracellular domain (ECD) or the Fzd8 ECD fusion molecule comprising a Fzd8 ECD and at least one fusion partner, wherein the Fzd8 ECD comprises the sequence of SEQ ID NO: 12 or a sequence that is 95% identical to the sequence of SEQ ID NO: 12. 2. A method of lowering a blood glucose level in a subject with a high blood glucose level comprising administering to the subject an effective amount of a frizzled-8 (Fzd8) extracellular domain (ECD) or a Fzd8 ECD fusion molecule comprising the Fzd8 ECD and at least one fusion partner, wherein the Fzd8 ECD comprises the sequence of SEQ ID NO: 12 or a sequence that is 95% identical to the sequence of SEQ ID NO: 12. 3. A method of reducing NPY expression in the hypothalamus of a subject in need of reduced NPY expression, comprising administering to the subject an effective amount of a frizzled-8 (Fzd8) extracellular domain (ECD) or the Fzd8 ECD fusion molecule comprising a Fzd8 ECD and at least one fusion partner, wherein the Fzd8 ECD comprises the sequence of SEQ ID NO: 12 or a sequence that is 95% identical to the sequence of SEQ ID NO: 12. 4. The method of any one of claims 1, 2, and 3, wherein the Fzd8 ECD has the sequence of SEQ ID NO.: 3, 4, 12, or 13. 5. The method of any one of claims 1, 2, and 3, wherein at least one fusion partner is selected from an Fc, albumin, and polyethylene glycol. 6. The method of claim 5, wherein at least one fusion partner is an Fc. 7. The method of any one of claims 1, 2, and 3, wherein the fusion molecule comprises a linker between the Fzd8 ECD and one or more fusion partners. 8. The method of any one of claims 1, 2, and 3, wherein the Fzd8 ECD fusion molecule comprises the amino acid sequence of SEQ ID NO.: 5, 6, 14, 15, 17, or 18. 9. The method of claim 8, wherein the Fzd8 ECD fusion molecule consists of the amino acid sequence of SEQ ID NO.: 5, 6, 14, 15, 17, or 18. 10. The method of any one of claims 1, 2, and 3, wherein the Fzd8 ECD comprises the sequence of SEQ ID NO: 4 or a sequence that is 95% identical to the sequence of SEQ ID NO: 4. 11. The method of any one of claims 1, 2, and 3, wherein the method further comprises administering a therapeutic agent selected from phentermine, orlistat, sibutramin HCl monohydrate, lorcaserin, phentermine/topiramate, naltrexone SR/bupropion SR, liraglutide, cetilistat, pramlintide/metreleptin, betahistine, zonisamide SR/bupropion SR, tesofensine, velneperit, davalintide, and obinepitide.

Details for Patent 8,431,532

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Chiesi Farmaceutici S.p.a.	MYALEPT	metreleptin	For Injection	125390	February 24, 2014		2030-06-28